The protean manifestations of rhabdomyosarcoma in childhood render it a-fascinating and challenging tumour to diagnose and treat. Rhabdomyosarcoma constitutes about 4% of all the malignant tumours seen in childhood and in England, Scotland and Wales, approximately 50 new cases occur annually in children under the age of 15 years (Draper et al., 1982) . The primary tumour develops in many sites but most frequently in the head and neck region, urogenital tract, trunk and extremities. Rhabdomyosarcoma is a highly malignant tumour with a tendency to infiltrate adjacent structures and to metastasise to lungs, bone, lymph nodes and sometimes to bone marrow. During the 1960's treatment with surgery and radiotherapy, either alone or in, combination, produced 5-year survival rates of 14-35% (Ehrlich et al., 1971; Kilman et al., 1973; Maurer et al., 1977; Sutow et al., 1970) . The introduction of multiple agent chemotherapy into treatment protocols during the early 1970's resulted in a considerable improvement in prognosis. Using the multimodality approach to treatment of rhabdomyosarcoma, disease-free survival rates of 90% at 3 years have been reported for patients presenting with non-metastatic disease in sites such as the orbit and genito-urinary tract. (Hays et al., 1981; Sutow et al., 1982) .
In January 1974 the Children's Solid Tumour Group (CSTG) was set up between St. Bartholomew's and the Royal Marsden Hospitals, with the objectives of improving the understanding of the biology of the solid tumours of childhood and of developing more effective treatment protocols.
Patients and methods
This report describes the experience of the CSTG for the period February 1974 to December 1981, during which time 73 children with rhabdomyosarcoma were treated by members of the group. The analysis of survival and relapse rates includes events occurring up to the end of December 1982.
Pathology
In all cases the diagnosis was confirmed by histological examination of the tumour tissue. Routine stains of the histological sections included haematoxylin and eosin, periodic acid schiff and phosphotungstic acid haematoxylin. Since 1977, tumour Tables I-III. Staging investigations After histological confirmation of the diagnosis, the investigations done as part of the initial staging assessment on all patients included full blood count, chest X-ray, bone scan, bone marrow aspirate and trephine. Other investigations such as abdominal ultrasound, C.T. scanning, i.v. urography, lymphangiography and lumbar puncture were done when appropriate.
Definition and evaluation of response (1) Complete response (CR):
disappearance of all evidence of disease for more than one month (2) Good partial response (GPR):
> 50% reduction in size of tumour at the primary site and clearance of metastatic disease for more than one month (3) Poor partial response (PPR):
< 50% reduction in size of tumour at the primary site but clearance of all metastatic disease for more than one month (4) No response (NR):
persistence or progression of disease. 
The relatively small number of very young boys with pelvic primary tumours included in this study is because these patients are usually referred to the Consultant Paediatric Urologist at the Hospital for Sick Children, Great Ormond Street.
Histological type
The distribution of cases by histological type is shown in Table VII . The embryonal/botryoid classification accounted for 76% of the cases. The alveolar type (22%) was seen predominantly in limb, pelvic and perineal sites. This predominance of alveolar histology in extremity lesions was also reported by the Intergroup rhabdomyosarcoma study IRS-1, (Hays et al., 1982a) .
Age distribution The frequency of rhabdomyosarcoma by age is shown in Figure 1 . Seventy three per cent of patients were aged <10 years at diagnosis. The median age was 6 years 2 months with a range of 2 weeks to 15 years 11 months. Lymphatic spread was not seen in any of the 16 children with orbital tumours, but was common in other head and neck sites (4/9). No lymphatic involvement was observed in any of the children with lesions of the trunk. The relative infrequency of lymphatic spread in patients with orbital and truncal lesions has also been noted by the Inter Group Rhabdomyosarcoma Study (Donaldson et al., 1973; Lawrence et al., 1977) .
Survival analysis
The median duration of follow up for this group of patients is 49 months with a range of 14-103 months. The predicted actuarial 5-year survival rate for all patients is 58% with a disease-free survival rate of 45% (Figure 2) . No relapse or death has been observed more than 4 years after diagnosis. Survival curves for patients staged according to the Barts/Marsden system are shown in Figure 5 . There is a predicted actuarial 5-year survival rate of 86% for all Stage I patients, 78% and 95% for Stage IA and IB respectively. This difference is not significant (P= 0.25) It therefore appears that surgical resection of locally-confined tumours does not make a significant difference to overall survival. This finding is of particular relevance for patients with orbital rhabdomyosarcoma for whom total excision of the tumour with enucleation used to be the treatment of choice. The poor survival rate of the Barts/Marsden Stage II patients (26%), with rates of 22% and 40% for BM Stages IIA and IIB respectively, means that both local extension of the tumour outside the tissue of origin and nodal spread are bad prognostic features.
In all three staging systems patients with metastatic disease do badly, with a survival rate of < 15% at 2 years. Of the 14 patients with generalised disease at presentation only one child is alive and disease free at 3 years from diagnosis.
Effect of site The best survival rates were seen in children with tumours of the orbit, the majority of whom had disease confined within the orbit. These children had a predicted 5-year survival rate of 94%. 
. Figure 6 ).
Effect of age
Age did not appear to have any significant effect on prognosis, and we did not find that infants have a worse prognosis than older children (Grosfield et al., 1969 (Figure 8 ).
Response to treatment
Eleven children required significant modifications to planned treatment because of drug toxicity or profound bone marrow suppression. Exclusion of a drug, reduction of drug dose by more than 33% of the planned dose, or a delay of more than 3 weeks in administering the drug were all considered as significant modifications to protocol. Of the 73 children, 52 (71%) achieved a complete remission on initial therapy, 6 patients achieved a good partial remission while a further five showed only a poor partial response. Four of the partial responders achieved a complete remission on subsequent therapy, and of these, 3 are alive and disease-free at intervals ranging from 13 months to 6 years. The overall complete response rate was therefore 77%. No child who failed to achieve a complete response is a long term survivor.
Ten patients failed to respond to initial therapy and of these, 6 had metastatic disease at diagnosis and the other 4 had evidence of nodal spread and/or locally invasive disease. The median duration of survival for the non responders was 24 weeks. Only 4 of the 14 children with metastatic disease at diagnosis achieved a complete remission and of ...
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1: 0' -? Figure 7 Effect of sex on overall survival in childhood rhabdomyosarcoma. (1979) . The median duration of survival from the time of first relapse was 6 months, with a range of 2 weeks to 70 months. Nine (47%) of the 19 children who relapsed, achieved a second complete remission with further therapy, whilst a further 2 patients are currently on treatment following a recent relapse. Four of the 9 children who achieved a complete response following a first relapse have had a second relapse, after disease free intervals ranging from 4 to 16 months. The other 5 children remain well and disease free at intervals ranging from 6 months to nearly 6 years. Five children have relapsed after more than 2 years following diagnosis, and of these, 4 have been boys with paratesticular primaries. The latest time at which a first relapse has been observed, occurred at 3 years from diagnosis.
Discussion
Radical changes in the management of rhabdomyosarcoma have occurred over the past decade and greater reliance is now placed on radiotherapy and chemotherapy to control local disease in sites where previously radical surgery would have been the treatment of choice. It is generally accepted that a multi-modality approach to the management of rhabdomyosarcoma provides the best chance of long term survival. However, the optimum duration and combination of therapies remain subjects of considerable debate. . . , . . . . . . . . . . . . . . . . . 1 . ] confounded by the fact that there is no universally accepted staging system for rhabdomyosarcoma. Due to the changing emphasis in treatment, the St. Jude system, first described by Pratt (1969) now seems inappropriate for many primary sites. The CSTG has defined a clinical classification, the Barts/Marsden staging system, which is similar to that described by Jaffe et al. (1973) . This system incorporates some of the more important concepts of both the St. Jude and the TNM classifications and appears to give a good differential with regard to outcome. In this series it has clearly shown that the children with the best prognosis are those with locally "confined" tumours (BM stages IA and IB) i.e. tumours which have not spread to nodes or distant sites and which have not infiltrated contiguous tissues. It has also shown that complete surgical resection of locally "confined" tumours does not improve prognosis as we have found no significant difference in outcome between patients with Stage IA and IB tumours. The Barts/Marsden system defines a subgroup of children who have tumours extending outside the tissue of origin to infiltrate contiguous tissue, usually bone (BM Stage IIA). These children do badly on standard treatment and should therefore be classified as "poor risk" patients. The system also shows that children with nodal involvement (BM Stage IIB) fare badly and confirms the findings of other classification systems that children with metastatic disease at diagnosis (BM Stage IIIA and IIIB) have a very poor prognosis.
The overall actuarial 5-year survival rate for children in our series was 58%, ranging from <15% in children with metastatic disease to 86% in children with locally confined tumours. These results are similar to those reported by the Intergroup Rhabdomyosarcoma Study Group (Maurer et al., 1977) .
In our series, the orbit was the most common primary site, and the children with tumours in this site were found to have the best prognosis, with a survival rate of 94% at 5 years. All but 2 of these children had Stage IA or B disease. This may reflect early detection of disease within the orbit. One other child has required a subsequent exenteration because of recurrent disease at the primary site. Rhabdomyosarcoma of the urogenital tract was the second commonest primary site in this series. Boys with paratesticular tumours and girls with vaginal primaries both appeared to have a good prognosis, whereas children with perineal, prostatic and unspecified pelvic primaries fared much less well. Nodal involvement was seen in 24% of children with tumours of the urogenital tract and lymphangiography should therefore be considered in all patients with tumours originating in these sites. In 1977 the committee for the Intergroup Rhabdomyosarcoma Study reported a 19% incidence of regional node involvement in children with genito-urinary rhabdomyosarcoma (Lawrence et al., 1977) and a subsequent report from the group (Tefft et al., 1980) described positive node involvement in 15/38 children who had undergone regional node sampling.
It is of interest that there appears to be a trend for girls to do less well than boys, although in this series the difference in survival fails to reach statistical significance. However, a similar trend which is statistically significant has been observed in an analysis of the national data collected by the Childhood Cancer Research Group in Oxford. (Stiller, 1982 personal communication) . In our series, the poorer prognosis for females appeared to be related to the higher proportion of females with tumours in unfavourable sites i.e. pelvic and nonorbital head and neck sites, who had more extensive disease at diagnosis. However, those findings were not corroborated in the national series, where an even distribution between the sexes was found for these sites.
In our series, children with tumours of alveolar histology, had a much poorer prognosis than those with embryonal histology with survival rates of 68% and 25% for embryonal and alveolar histologies respectively. This finding is similar to that observed by the Intergroup rhabdomyosarcoma study who reported a mortality of 62% in patients with alveolar histology compared to 38% in children with embryonal histology (Hays et al., 1982b) . However, in our series the poor prognosis of children with tumours of alveolar histology was also related to the stage of the disease, as 87% of the children with alveolar histology had "'unconfined" tumours (BM stages II and III) compared to only 33% of children with embryonal histology. It would therefore appear that tumours of alveolar histology have a tendency to infiltrate locally and to metastasise to distant sites.
Although 77% of the patients eventually achieved a complete response, it was disappointing to find that over a third (37%) of these patients subsequently relapsed. Recurrent disease at the primary site was present in 58% of the patients who relapsed. The long term salvage rate following a relapse was only 15%. The median time to first relapse was 14.5 months, and it is chastening to find that there are a significant number of relatively "late" relapses, 5 out of 19 occurring more than 2 years from diagnosis, emphasising the need for long term surveillance of these children (Maurer et al., 1977) .
The advent of CT scanning has made a considerable contribution to the management of rhabdomyosarcoma and embryonal sarcoma, both in the initial assessment at diagnosis and in subsequent evaluation and follow up. It has been of particular value in children with primary lesions in the pelvis and nasopharynx, where it has been able to demonstrate the very extensive nature of many of the tumours in these sites. A more aggressive approach in the treatment of tumours of the nasopharynx was introduced by the CSTG in 1977, but as yet the number of children treated on the more intensive protocol is too small to say whether the intensification of therapy has made a significant impact on prognosis. Similarly children with pelvic primaries require aggressive therapy to achieve control of their disease, and the results of our recent treatment protocols for tumours in these sites remain disappointingly poor.
In conclusion, it is encouraging that considerable improvements in prognosis have resulted from the introduction of a multimodality approach to the treatment of rhabdomyosarcoma and embryonal sarcoma. Eighty-five per cent of children with locally "confined" tumours can now expect to survive for 5 years and are hopefully cured of their disease. Unfortunately, the prognosis for children with "unconfined"' disease remains extremely poor, and it is in these children that new therapeutic approaches are required. Responses to high dose chemotherapy have been seen in children with relapsed rhabdomyosarcoma resistant to conventional doses of cytotoxic agents. Members of the CSTG are therefore currently assessing the value of high dose melphalan with autologous marrow rescue, used in an adjuvant role following 6 courses of chemotherapy at conventional dosage, for patients defined as poor risk i.e. those with "unconfined" or advanced stage disease.
